Clinical trials: Hep A
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Hepatitis C, Chronic
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
The primary objective of this pilot trial is to compare the efficacy, measured as sustained virologic response (SVR) at least 12 weeks after completion of therapy, across three study regimens/delivery modalities: Arm 1 - 4 weeks…
- Trial name
- NCT03480932
- Testing
- Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hepatitis C, HIV
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
Primary Objective: This study will evaluate the effectiveness of an HCV Care Facilitation intervention in moving HIV/HCV co-infected substance users forward along the HCV care continuum (compared with a Control group).
- Conditions
- Hepatitis C, HIV, AIDS, Substance Use
- Trial name
- CTN 0064 (NCT02641158)
- Testing
- Control Group, Care Facilitation Group
- Where
- 11 sites in United States
- Volunteers
- 422 people
- Sponsor
- Columbia University
Chronic Hepatitis C
Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Background: Chronic hepatitis C is a serious liver disease. Current treatments have side effects. New drugs have been developed, but they work better in some people than others. Researchers want to learn why.
- Trial name
- NCT02468648
- Testing
- Sofosbuvir, GS-5816
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Male Participants
A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients
The purpose of this study is to evaluate the absolute bioavailability and pharmacokinetics (what the body does to the medication) of simeprevir (TMC435) after administration of single oral doses of 50 mg and 150 mg when…
- Trial name
- NCT01707342
- Testing
- Simeprevir (TMC435)
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Janssen R&D Ireland
HIV Infections, Hepatitis C
Multicenter Performance Study of QuadQuik Invitro Diagnostic Device
To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device
- Conditions
- HIV Infections, Hepatitis C, Hepatitis B, Syphilis Infection
- Trial name
- NCT05692505
- Testing
- QuadQuik
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genlantis Diagnostics
Hepatitis B
To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.
Study population:Person with HBeAg negative CHB on TDF/ETV for more than 1 year Study design:Prospective,Interventional (single arm study) Sample size: All the patients fulfilling the inclusion criteria will be included in first…
- Trial name
- NCT03123653
- Testing
- Peg IFN 2b
- Where
- India
- Volunteers
- 118 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Intensive Care Unit
Incidence Of Hepatitis In Intensive Care Unit
The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital and The…
- Trial name
- NCT03456037
- Testing
- hepatitis viruses
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Sakarya University
Diphtheria, Tetanus
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks
A multicenter, observational study to evaluate the safety of Euforvac-Hib vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B in infants.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02257645
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
The purpose of this study is to evaluate the immunogenicity and safety of two doses of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when co-administered with GSK Biologicals' HAV vaccine according to 0, 6 month schedule…
- Trial name
- NCT02082639
- Testing
- Cervarix™, Havrix
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM
Peg interferon and ribavirin currently represent the standard approved association for treating patients infected with hepatitis C virus (HCV) .
- Trial name
- CINAM (NCT00199719)
- Testing
- Ribavirine
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Limoges
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Infectious Disease
HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment
Hepatitis C infection is a major cause of chronic liver disease and death with approximately 3% of the world's population is infected with hepatitis C virus (HCV).
- Trial name
- NCT03524794
- Where
- United Kingdom
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- University College, London
Healthy Infants
A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants
To evaluate and compare the immunogenicity of Eutravac (Diphtheria-Tetanus-acellular Pertussis [DTaP] Hepatitis B [HB] combined) vaccine with separate but simultaneous administrations of DTaP and HB vaccine each administered to…
- Trial name
- NCT01896739
- Testing
- Eutravac
- Where
- 7 sites in South Korea
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Cardiac Transplant Disorder, Hepatitis C
Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant
This is a proof of concept, single center study for the donation of HCV-positive hearts to HCV negative recipient patients, with preemptive, interventional treatment with 12-16 weeks of grazoprevir and elbasvir (with or without…
- Trial name
- NCT03026023
- Testing
- Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
- Where
- United States
- Sponsor
- Raymond T. Chung, MD
Antiviral Treatment of Chronic Hepatitis B
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
Patients with spontaneous decline of HBV DNA were non-randomly assigned to accept peginterferon alfa-2a or entecavir therapy, or didn't accept any antiviral regiment.
- Trial name
- NCT01892241
- Testing
- Pegasys(Roche), Entecavir
- Volunteers
- 74 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Hepatitis C, Hepatitis B
Australian Hepatitis and Risk Survey in Prisons
The Australian Hepatitis and risk survey in prisons (AusHep) is a national prison-based blood-borne virus (BBV) surveillance study.
- Conditions
- Hepatitis C, Hepatitis B, HIV Infections
- Trial name
- AusHep (NCT05839522)
- Testing
- Point-of-care hepatitis C antibody test, Point-of-care hepatitis C RNA test, Point-of-care hepatitis B surface antibody test
- Where
- 24 sites in Australia
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in adults with chronic hepatitis C virus…
- Trial name
- NCT03074331
- Testing
- SOF/VEL
- Where
- 16 sites in India
- Volunteers
- 130 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265
This multicenter, prospective, observational study will evaluate the one-year outcomes in HBeAg positive chronic hepatitis B patients who had received Pegasys (peginterferon alfa-2a) in Arm A of study ML22265.
- Trial name
- NCT01645969
- Where
- 5 sites in China
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.